120 related articles for article (PubMed ID: 3874720)
1. Comparison of leucovorin protection from variety of antifolates in human lymphoid cell lines.
Browman GP; Spiegl P; Booker L; Rosowsky A
Cancer Chemother Pharmacol; 1985; 15(2):111-4. PubMed ID: 3874720
[TBL] [Abstract][Full Text] [Related]
2. Differential calcium leucovorin protection of human lymphoid cell lines from methotrexate.
Browman GP; Booker L; Spiegl P
Cancer Chemother Pharmacol; 1985; 15(2):105-10. PubMed ID: 2410158
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
Miyachi H; Takemura Y; Kobayashi H; Ando Y
Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939
[TBL] [Abstract][Full Text] [Related]
4. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ
Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986
[TBL] [Abstract][Full Text] [Related]
5. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance.
Jansen G; Mauritz R; Drori S; Sprecher H; Kathmann I; Bunni M; Priest DG; Noordhuis P; Schornagel JH; Pinedo HM; Peters GJ; Assaraf YG
J Biol Chem; 1998 Nov; 273(46):30189-98. PubMed ID: 9804775
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity of methotrexate and trimetrexate and its reversal by folinic acid in human leukemic CCRF-CEM cells with carrier-mediated and receptor-mediated folate uptake.
van der Veer LJ; Westerhof GR; Rijksen G; Schornagel JH; Jansen G
Leuk Res; 1989; 13(11):981-7. PubMed ID: 2532692
[TBL] [Abstract][Full Text] [Related]
7. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
[TBL] [Abstract][Full Text] [Related]
8. 5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines.
Pizzorno G; Cashmore AR; Moroson BA; Cross AD; Smith AK; Marling-Cason M; Kamen BA; Beardsley GP
J Biol Chem; 1993 Jan; 268(2):1017-23. PubMed ID: 8419310
[TBL] [Abstract][Full Text] [Related]
9. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
10. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
Diddens H; Niethammer D; Jackson RC
Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
[TBL] [Abstract][Full Text] [Related]
11. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
Matherly LH; Angeles SM; McGuire JJ
Biochem Pharmacol; 1993 Dec; 46(12):2185-95. PubMed ID: 7506026
[TBL] [Abstract][Full Text] [Related]
12. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
[TBL] [Abstract][Full Text] [Related]
13. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
[TBL] [Abstract][Full Text] [Related]
14. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates.
Kobayashi H; Takemura Y; Ohnuma T
Cancer Lett; 1998 Feb; 124(2):135-42. PubMed ID: 9500202
[TBL] [Abstract][Full Text] [Related]
15. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and growth inhibition studies of methotrexate and aminopterin analogues containing a tetrazole ring in place of the gamma-carboxyl group.
McGuire JJ; Russell CA; Bolanowska WE; Freitag CM; Jones CS; Kalman TI
Cancer Res; 1990 Mar; 50(6):1726-31. PubMed ID: 2306727
[TBL] [Abstract][Full Text] [Related]
17. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
Takemura Y; Ohnuma T
Mt Sinai J Med; 1992 Oct; 59(5):419-24. PubMed ID: 1435841
[TBL] [Abstract][Full Text] [Related]
18. Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport-related methotrexate resistance.
Jansen G; Westerhof GR; Kathmann I; Rademaker BC; Rijksen G; Schornagel JH
Cancer Res; 1989 May; 49(9):2455-9. PubMed ID: 2706633
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines.
Mini E; Moroson BA; Franco CT; Bertino JR
Cancer Res; 1985 Jan; 45(1):325-30. PubMed ID: 3855284
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate.
van der Laan BF; Jansen G; Kathmann GA; Westerhof GR; Schornagel JH; Hordijk GJ
Int J Cancer; 1992 Jul; 51(6):909-14. PubMed ID: 1639538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
